Optimum anthracycline-based chemotherapy for early breast cancer (Q34571917)

3 August 2017

1 reference

title

Optimum anthracycline-based chemotherapy for early breast cancer (English)

1 reference

3 August 2017

1 reference

J W Adlard

1

1 reference

3 August 2017

D J Dodwell

series ordinal

2

1 reference

3 August 2017

publication date

1 August 2001

1 reference

Lancet Oncology Commission

3 August 2017

published in

1 reference

3 August 2017

volume

2

1 reference

3 August 2017

issue

8

1 reference

3 August 2017

page(s)

469-474

1 reference

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

The importance of dose intensity in chemotherapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

Tolerance of radiotherapy combined with adjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

Risk of leukemia after chemotherapy and radiation treatment for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2801%2900452-1

7 January 2021

10.1016/S1470-2045(01)00452-1

Identifiers

DOI

1 reference

release_p5ofobcj7rgjjic3s2ulvbtpxe

3 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/p5ofobcj7rgjjic3s2ulvbtpxe

24 November 2022

mapped directly with Wikidata item

1 reference